FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Levofloxacin (LEVAQUIN) Injection
Status: Discontinuation
»Therapeutic Categories: Anti-Infective

Janssen Pharmaceuticals (New 07/31/2015)

Company Contact Information:
800-526-7736

Presentation Posting Date Related Information
Levofloxacin (LEVAQUIN) Injection 5 mg/mL in 5% Dextrose) Premix in Single-Use Flexible Containers. 07/31/2015 Janssen Pharmaceuticals has made a business decision to permanently discontinue LEVAQUIN® (levofloxacin) Injection (5 mg/mL in 5% Dextrose) Premix in Single-Use Flexible Containers. Product should be maintained on the formularies until the last batch of each strength produced expires (January 31, 2015 (250 mg in 50 mL), June 30, 2015 (500 mg in 100 mL) and July 31, 2015 (750 mg in 150 mL) in order to maintain continuity of the reimbursement process.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English